Cargando…
A Case of Macrophage Activation Syndrome During the Treatment of Adult-onset Still’s Disease With Tocilizumab
Macrophage activation syndrome (MAS) is a fatal complication of adult-onset Still’s disease (AOSD). Although anti-cytokine agents have been recommended for refractory AOSD or complicated with MAS, MAS cases have been rarely reported during anti-cytokine treatment. Herein, we describe the first AOSD...
Autores principales: | Lee, Ju Ho, Ha, You-Jung, Kang, Eun Ha, Chang, Sung Hae, Lee, Yun Jong, sup, 3 |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Rheumatology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327616/ https://www.ncbi.nlm.nih.gov/pubmed/37475901 http://dx.doi.org/10.4078/jrd.2022.29.2.123 |
Ejemplares similares
-
Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review
por: Watanabe, Eri, et al.
Publicado: (2016) -
Adult-onset Still's Disease during Pregnancy Treated with Tocilizumab
por: Imaizumi, Chihiro, et al.
Publicado: (2022) -
Tocilizumab-Induced Acute Liver Injury in Adult Onset Still's Disease
por: Drepper, Michael, et al.
Publicado: (2013) -
A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
por: Li, Ting, et al.
Publicado: (2017) -
Adult‐onset Still's disease complicated by macrophage activation syndrome
por: Awoyemi, Toluwalase, et al.
Publicado: (2023)